—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Halozyme Therapeutics Inc (HALO) — Technical state

As of 2026-11-02 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.

The Closelooknet read

  • Closelooknet score: 73 out of 100 (momentum 97 · quality 94 · valuation 38), as of 2026-11-03.
  • Signal: Uptrend stack intact — Trades +13% vs the 50-day and +54.1% vs the 200-day average, 3.8% below the 52-week high and +110.6% off the 52-week low. Computed from daily closes. (as of 2026-11-02)
  • Trend: Halozyme Therapeutics Inc trades 13.0% above its 50-day and 54.1% above its 200-day moving average. (as of 2026-11-02)

Halozyme develops and licenses an enzyme called rHuPH20, which lets injectable biologic drugs be given under the skin instead of by intravenous infusion. It sells this enzyme technology to large drug makers, who build it into subcutaneous versions of their antibody treatments, and it also sells a small number of its own products directly.

The full read — the desk's view, the earnings record, peers and the company snapshot — is on the HALO overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Uptrend stack intact

Trades +13% vs the 50-day and +54.1% vs the 200-day average, 3.8% below the 52-week high and +110.6% off the 52-week low. Computed from daily closes.

Ranked #3 on today’s Directional Flow — near their highs list (scan of 2026-11-02).

The moving-average stack

Continue: the HALO chart & overview · quality & forensics · the earnings record · the signal board

FAQ · from the current data · as of 2026-11-02

Quick answers

What is the current Closelooknet signal on HALO?

Uptrend stack intact — Trades +13% vs the 50-day and +54.1% vs the 200-day average, 3.8% below the 52-week high and +110.6% off the 52-week low. Computed from daily closes. As of 2026-11-02; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.

Is HALO above its 50-day and 200-day moving averages?

As of 2026-11-02, Halozyme Therapeutics Inc trades +13% above its 50-day and +54.1% above its 200-day average, with the 20-day +6.5% away.

How far is HALO from its 52-week high?

3.8% below the 52-week high and 110.6% above the 52-week low, as of 2026-11-02.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.